(Q46008192)

18 December 2017

meta-analysis

0 references

title

Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. (English)

1 reference

18 December 2017

cost-effectiveness analysis

1 reference

1 reference

1 reference

1 reference

2

1 reference

18 December 2017

Dyfrig A. Hughes

series ordinal

4

1 reference

18 December 2017

author name string

J Pink

series ordinal

1

1 reference

18 December 2017

S Lane

series ordinal

3

1 reference

18 December 2017

language of work or name

English

0 references

publication date

23 September 2013

1 reference

18 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

18 December 2017

volume

95

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

199-207

1 reference

18 December 2017

Dabigatran versus warfarin in patients with atrial fibrillation

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Effect of Home Testing of International Normalized Ratio on Clinical Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Economic evaluations during early (phase II) drug development: a role for clinical trial simulations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Warfarin pharmacogenetics: economic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Discrete event simulation: the preferred technique for health economic evaluations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

New oral anticoagulants for atrial fibrillation: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Guidelines on oral anticoagulation (warfarin): third edition--2005 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Risk factors for nonadherence to warfarin: results from the IN-RANGE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Integration of genetic, clinical, and INR data to refine warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Representing uncertainty: the role of cost-effectiveness acceptability curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

Warfarin pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.190

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2013.190

1 reference

18 December 2017

Dimensions Publication ID

1012638107

0 references

1 reference

18 December 2017